Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis - Elk Valley Times

July 17, 2026

Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis

April 2, 2026

B The company is set to launch on an immediate basis MUMBAI, India and WARREN, N.J., April 3, 2026 /PRNewswire/ — Cipla USA Inc. the…

posteditor

Articles: 16137

Accessibility Adjustments

Powered by OneTap

Select your accessibility profile

Vision Impaired Mode

Enhances website's visuals

Seizure Safe Profile

Clear flashes & reduces color

ADHD Friendly Mode

Focused browsing, distraction-free

Blindness Mode

Reduces distractions, improves focus

Epilepsy Safe Mode

Dims colors and stops blinking

Content Modules

Font Size

Default

Line Height

Default

Color Modules

Orientation Modules

Skip To Content